Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, United States; Fischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, MD, 20742, United States.
Adv Drug Deliv Rev. 2022 Sep;188:114415. doi: 10.1016/j.addr.2022.114415. Epub 2022 Jul 3.
Glioblastoma (GBM) is the most common malignant adult brain cancer with no curative treatment strategy. A significant hurdle in GBM treatment is effective therapeutic delivery to the brain-invading tumor cells that remain following surgery within functioning brain regions. Developing therapies that can either directly target these brain-invading tumor cells or act on other cell types and molecular processes supporting tumor cell invasion and recurrence are essential steps in advancing new treatments in the clinic. This review highlights some of the drug delivery strategies and nanotherapeutic technologies that are designed to target brain-invading GBM cells or non-neoplastic, invasion-supporting cells residing within the GBM tumor microenvironment.
胶质母细胞瘤（GBM）是最常见的成人脑恶性肿瘤，目前尚无有效的治疗策略。GBM 治疗的一个显著障碍是在手术切除后，如何将治疗药物有效地递送到功能区残留的脑侵袭性肿瘤细胞中。开发能够直接针对这些脑侵袭性肿瘤细胞或针对其他支持肿瘤细胞侵袭和复发的细胞类型和分子过程的治疗方法，是将新的治疗方法推向临床应用的重要步骤。本综述重点介绍了一些旨在靶向脑侵袭性 GBM 细胞或存在于 GBM 肿瘤微环境中的非肿瘤侵袭性支持细胞的药物传递策略和纳米治疗技术。
